[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626278":3},{"organization":4,"armGroups":7,"interventions":54,"overallOfficials":71,"centralContacts":76,"locations":82,"responsibleParty":99,"collaborators":59,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":59,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":59,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":59,"overallStatus":85,"whyStopped":59,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Il-Yang Pharm. Co., Ltd.","INDUSTRY",[8,15,19,23,27,31,35,39,43,49],{"label":9,"type":10,"description":11,"interventionNames":12},"(SAD) IY-828026 10 mg","EXPERIMENTAL","Paritipants will receive single oral administration of IY-828026 10 mg or Placebo comparator",[13,14],"Drug: IY-828026","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"(SAD) IY-828026 20 mg","Paritipants will receive single oral administration of IY-828026 20 mg or Placebo comparator",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"(SAD) IY-828026 40 mg","Period 1: Paritipants will receive single oral administration of IY-828026 40 mg or Placebo comparator (Fast) Period 2: Paritipants will receive single oral administration of IY-828026 40 mg or Placebo comparator (Fed)",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"(SAD) IY-828026 80 mg","Paritipants will receive single oral administration of IY-828026 80 mg or Placebo comparator",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"(SAD) IY-828026 160 mg","Paritipants will receive single oral administration of IY-828026 160 mg or Placebo comparator",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"(MAD) IY-828026 20 mg","Participants will receive oral administration of IY-828026 20 mg once daily for 7 days",[13,14],{"label":36,"type":10,"description":37,"interventionNames":38},"(MAD) IY-828026 40 mg","Participants will receive oral administration of IY-828026 40 mg once daily for 7 days",[13,14],{"label":40,"type":10,"description":41,"interventionNames":42},"(MAD) IY-828026 80 mg","Participants will receive oral administration of IY-828026 80 mg once daily for 7 days",[13,14],{"label":44,"type":45,"description":46,"interventionNames":47},"(MAD) IY-828026A","ACTIVE_COMPARATOR","Participants will receive oral administration of IY-828026A 40mg once daily for 7 days",[48],"Drug: IY-828026A",{"label":50,"type":45,"description":51,"interventionNames":52},"(MAD) IY-828026B","Participants will receive oral administration of IY-828026B 50mg once daily for 7 days",[53],"Drug: IY-828026B",[55,60,64,68],{"type":56,"name":57,"description":57,"armGroupLabels":58,"otherNames":59},"DRUG","IY-828026",[32,36,40,9,28,16,20,24],null,{"type":56,"name":61,"description":62,"armGroupLabels":63,"otherNames":59},"Placebo","Placebo comparator",[32,36,40,9,28,16,20,24],{"type":56,"name":65,"description":66,"armGroupLabels":67,"otherNames":59},"IY-828026A","Active comparator",[44],{"type":56,"name":69,"description":66,"armGroupLabels":70,"otherNames":59},"IY-828026B",[50],[72],{"name":73,"affiliation":74,"role":75},"Shin","Ilyang Pharmaceutical","STUDY_DIRECTOR",[77],{"name":78,"role":79,"phone":80,"phoneExt":59,"email":81},"YunSeon Kim","CONTACT","82-70-7165-7319","yskim@ilyang.co.kr",[83],{"facility":84,"status":85,"city":86,"state":59,"zip":59,"country":87,"countryCode":59,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Seoul National University Hospital","RECRUITING","Seoul","South Korea",{"type":89,"coordinates":90},"Point",[91,92],126.9784,37.566,{"lat":92,"lon":91},[95],{"name":96,"role":79,"phone":97,"phoneExt":59,"email":98},"Injin Jang, M.D.\u002FPh.D.","82-2-2027-4269","ijjang@snu.ac.kr",{"type":100,"investigatorFullName":59,"investigatorTitle":59,"investigatorAffiliation":59,"oldNameTitle":59,"oldOrganization":59},"SPONSOR","100626278","phase-1-safety-tolerability-pharmacokinetic-and-pharmacodynamic-of-iy-828026-in-healthy-volunteers-100626278",false,"NCT07433556","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","A Randomized, Double-blinded, Partial-open, Placebo\u002FActive-controlled, Single\u002FMultiple Dosing, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of IY-828026 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥ 19 and ≤ 50 years at screening\n* Body weight ≥ 50.0 kg to ≤ 90.0 kg and body mass index (BMI) of ≥ 18.5 kg\u002Fm2 to ≤ 29.9 kg\u002Fm2 at screening\n* Volunteers who were fully informed of and completely understood this study, voluntarily agreed to participate, and provided written consent to comply with the precautions\n\nExclusion Criteria:\n\n* Current or history of clinically significant disease of hepatobiliary (severe hepatic impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, gastrointestinal, endocrine, hemato-oncologic, cardiovascular (heart failure, torsades de pointes, etc.), urinary, or psychiatric (mood disorder, obsessive compulsory disorder, etc.) system or sexual dysfunctions\n* H. pylori eradication treatment within 6 months or positive result for H. pylori at screening\n* Hypersensitivity or history of clinically significant hypersensitivity to PPIs, P-CABs, and other drugs (aspirin, antibiotics, etc.)\n* A positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus \\[HIV\\] tests, or syphilis tests)\n* History of drug abuse or positive results for drug abuse in the urine drug screen",true,"ALL","19 Years","50 Years",{"count":113,"type":114},86,"ESTIMATED","INTERVENTIONAL",[117],"PHASE1","A randomized, double-blinded, partial-open, placebo\u002Factive-controlled, single\u002Fmultiple dosing, dose escalation phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IY-828026 in healthy adult volunteers",[120],"Healhty","2026-03-23",{"date":123,"type":124},"2026-03-27","ACTUAL",{"date":121,"type":124},{"date":127,"type":114},"2027-06",{"name":5,"class":6},1]